Practo names Jagnoor Singh CEO as cofounder Shashank ND becomes executive chairman

Former COO Jagnoor Singh takes over as CEO from September 1, while cofounder Shashank ND moves to MD and executive chairman. The consumer-health platform is reportedly seeking $100M-$125M in pre-IPO funding ahead of a targeted 2027 listing.

— Source publishedThu, 17 Sept, 2026, 12:17 IST·First seen Thu, 17 Sept, 2026, 12:50 IST·Source Inc42

What happened

Practo appointed former COO Jagnoor Singh CEO, with cofounder Shashank ND becoming MD and executive chairman. The Indian consumer-health platform is expanding

Key facts

  • 40% YoY growth
  • Profitable for 2.5 years
  • FY25 operating EBITDA: ₹15 Cr
  • FY25 revenue: ₹234 Cr
  • FY24 EBITDA loss: ₹17 Cr
  • FY24 revenue: ₹240 Cr
  • 40 co-branded dermatology clinics in India
  • More than 7 Lakh doctors and healthcare providers
  • Over 2,400 cities globally
  • More than 500 Insta clients across 1,200 facilities
  • Proposed pre-IPO funding: $100 Mn-$125 Mn
  • Reported post-money valuation: about $700 Mn
  • Total funding raised: about $230 Mn

Why this matters

With a new operating CEO and founder-led board oversight, Practo may be better positioned to pursue international partnerships or acquisitions that accelerate scale before going public.

What to watch

  • Confirmation of the $100M-$125M round, valuation, lead investor and use-of-proceeds.
  • New independent directors, CFO changes, auditor appointments or formal IPO-preparation disclosures.
  • International launch announcements, local clinical partnerships and regulatory approvals.
  • Quarterly indicators of consultation growth, take rate, repeat usage, EBITDA trajectory and cash burn.
  • Founder Shashank ND's continued role in product, capital allocation and major strategic decisions.
  • Appoint or elevate finance, compliance, investor-relations and international-market leaders.
  • Set public KPI targets around profitability, repeat consultations, provider retention and contribution margin.
  • Begin pre-IPO governance upgrades, including board independence, audit controls and reporting discipline.
  • Use new capital to expand selective overseas offerings and deepen high-margin care pathways such as diagnostics, subscriptions and enterprise health.

Also reported by